Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-Current Debt (2020 - 2025)

Rani Therapeutics Holdings has reported Non-Current Debt over the past 5 years, most recently at $2.2 million for Q2 2025.

  • Quarterly results put Non-Current Debt at $2.2 million for Q2 2025, down 87.05% from a year ago — trailing twelve months through Jun 2025 was $2.2 million (down 87.05% YoY), and the annual figure for FY2024 was $9.6 million, down 60.74%.
  • Non-Current Debt for Q2 2025 was $2.2 million at Rani Therapeutics Holdings, down from $5.9 million in the prior quarter.
  • Over the last five years, Non-Current Debt for RANI hit a ceiling of $29.3 million in Q2 2023 and a floor of $2.2 million in Q2 2025.
  • Median Non-Current Debt over the past 4 years was $19.0 million (2024), compared with a mean of $18.6 million.
  • Biggest five-year swings in Non-Current Debt: soared 99.43% in 2023 and later plummeted 87.05% in 2025.
  • Rani Therapeutics Holdings' Non-Current Debt stood at $29.1 million in 2022, then dropped by 16.0% to $24.5 million in 2023, then crashed by 60.74% to $9.6 million in 2024, then crashed by 76.81% to $2.2 million in 2025.
  • The last three reported values for Non-Current Debt were $2.2 million (Q2 2025), $5.9 million (Q1 2025), and $9.6 million (Q4 2024) per Business Quant data.